Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment-Resistant Hypertension Clear all
Completed No phase listed Observational

REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management

NCT00370214
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
3 Months and older
Enrollment
3,515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
54
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Not applicable Interventional

Lifestyle Interventions in Treatment-Resistant Hypertension

NCT02342808
View directory record Official record
Conditions
Treatment-Resistant Hypertension
Interventions
Structured center-based lifestyle intervention, Standard education and physician advice
Behavioral
Lead sponsor
Duke University
Other
Eligibility
35 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 14, 2026, 9:23 AM EDT
Terminated Phase 3 Interventional

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

NCT00389675
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
85
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 14, 2026, 9:23 AM EDT
Terminated Phase 3 Interventional

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

NCT04857840
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Firibastat (QGC001) Period 1
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years to 99 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 14, 2026, 9:23 AM EDT
Not yet recruiting Not applicable Interventional

The RESPLASH Study

NCT06880562
View directory record Official record
Conditions
Resistant Hypertension
Interventions
Splanchnic Nerve Denervation, Renal Denervation Only
Device
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Phase 3 Interventional

Firibastat in Treatment-resistant Hypertension

NCT04277884
View directory record Official record
Conditions
Hypertension
Interventions
Firibastat, Placebo
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Huntington Beach, California • Tustin, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

NCT00417170
View directory record Official record
Conditions
High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Interventions
Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

NCT02133872
View directory record Official record
Conditions
Hypertension
Interventions
Minocycline 50mg/d, Minocycline 100mg/d, Minocycline 200mg/d
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Phase 4 Interventional

Yoga for the Management of HIV-Metabolic Syndromes

NCT00627380
View directory record Official record
Conditions
HIV Infections, HIV Metabolic Cardiovascular Syndrome, HIV Lipodystrophy, HIV Metabolic Syndromes, Hypertension
Interventions
Yoga lifestyle intervention, Standard of care
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 25, 2010 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension

NCT01673373
View directory record Official record
Conditions
Renal Artery Stenosis, Hypertension, Renovascular
Interventions
iCAST™ Rx Stent System
Device
Lead sponsor
Atrium Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
12
States / cities
Fremont, California • Loveland, Colorado • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

NCT00817635
View directory record Official record
Conditions
Hypertension
Interventions
LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Mobile, Alabama • Sierra Vista, Arizona • Buena Park, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment

NCT01897727
View directory record Official record
Conditions
Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism
Interventions
Spironolactone, BP medication uptitration
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

NCT02515331
View directory record Official record
Conditions
Patients, Resistant Hypertension
Interventions
LHW090, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • North Hollywood, California • Atlantis, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 14, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional

Tezosentan in Pulmonary Arterial Hypertension

NCT01077297
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tezosentan
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 14, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

NCT02232880
View directory record Official record
Conditions
Hypertension
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 14, 2026, 9:23 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Truway Diagnostic Tools in Primary Care

NCT07209527
View directory record Official record
Conditions
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions
Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Phase 3 Interventional

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

NCT00389779
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
87
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 14, 2026, 9:23 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

MANP in African Americans With Hypertension

NCT04542681
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy
Interventions
Placebo - 1st Cycle, MANP - 1st Cycle, MANP - 2nd Cycle
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Not applicable Interventional

A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome

NCT00940966
View directory record Official record
Conditions
Elevated Triglycerides, Systolic Hypertension, Insulin Resistance, Abdominal Obesity
Interventions
standard ADA diet, energy restricted very-low carbohydrate diet, low glycemic diet
Dietary Supplement
Lead sponsor
CAMC Health System
Other
Eligibility
12 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

Rheos® Pivotal Trial

NCT00442286
View directory record Official record
Conditions
Hypertension
Interventions
Rheos® Baroreflex Hypertension System
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Not applicable Interventional

Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study

NCT02167464
View directory record Official record
Conditions
Hypertension
Interventions
Renin treatment-guided Therapeutics, Referral Hypertension specialist, Aldosterone Antagonist
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Anderson, South Carolina • Beaufort, South Carolina • Florence, South Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Sep 14, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

NCT03541174
View directory record Official record
Conditions
Resistant Hypertension
Interventions
Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
41
States / cities
Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 14, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional Results available

Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

NCT03273257
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions
Riociguat, Placebo, Pulmonary endarterectomy
Drug · Procedure
Lead sponsor
International CTEPH Association
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 14, 2026, 9:23 AM EDT